HUCMNCs Protect Vascular Endothelium and Prevent ISR After Endovascular Interventional Therapy for Vascular Diseases in T2DM Rabbits

Overview

Journal Mol Cell Biochem

Publisher Springer

Specialty Biochemistry

Date 2017 May 6

PMID 28474283

Citations 2

Authors

Haixia Ding

Tong Zhang

Yaping Du

Bei Liu

Yueqin Liu

Fujun Wang

Affiliations

Soon will be listed here.

Abstract

The therapeutic effect of transplantation of human umbilical cord blood cell-derived mononuclear cells (HUCMNCs) on treating in-stent restenosis (ISR) after endovascular interventional therapy (EIT) was evaluated in preclinical rabbit model of type 2 diabetes mellitus (T2DM)-related peripheral artery disease (PAD). HUCMNCs were transplanted to T2DM rabbits subjected to femoral artery occlusion surgery and received EIT. Serum concentration of soluble vascular endothelial cadherin (VE-cad) and plasma concentration of lipoprotein-associated phospholipase A2 (Lp-PLA2) were determined with enzyme-linked immunosorbent assay before and after the transplantation. The injury and the recovery of right femoral artery at stenting site were evaluated with Hematoxylin and Eosin (HE) staining. HUCMNCs purified from umbilical cord blood were 100% CD45 and 96.5% CD34 with round or oval morphology and adherent growth pattern. The soluble VE-cad and Lp-PLA2 were significantly attenuated after HUCMNC transplantation. The intimal area and the ratio between intimal area and medium film area in the dilated occlusion site were also dramatically decreased 4 weeks after receiving HUCMNCs. HUCMNC transplantation is effective in protecting vascular endothelial function and preventing ISR after EIT in T2DM rabbits suffering from PAD.

Citing Articles

Effect of umbilical cord blood stem cell transplantation on restenosis after endovascular interventional therapy for diabetic hindlimb vascular disease.

Ding H, Xing N, Ma H, Hou L, Zhou C, Du Y PLoS One. 2021; 16(8):e0255162.

PMID: 34379650 PMC: 8357084. DOI: 10.1371/journal.pone.0255162.

The effect of endothelial progenitor cell transplantation on neointimal hyperplasia and reendothelialisation after balloon catheter injury in rat carotid arteries.

Wang W, Zhang Y, Hui H, Tong W, Wei Z, Li Z Stem Cell Res Ther. 2021; 12(1):99.

PMID: 33536065 PMC: 7860581. DOI: 10.1186/s13287-021-02135-w.

References

Shinozuka K, Dailey T, Tajiri N, Ishikawa H, Kaneko Y, Borlongan C . Stem cell transplantation for neuroprotection in stroke. Brain Sci. 2013; 3(1):239-61. PMC: 3800120. DOI: 10.3390/brainsci3010239. View

Kornowski R, Hong M, Tio F, Bramwell O, Wu H, Leon M . In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol. 1998; 31(1):224-30. DOI: 10.1016/s0735-1097(97)00450-6. View

Sata M, Saiura A, Kunisato A, Tojo A, Okada S, Tokuhisa T . Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med. 2002; 8(4):403-9. DOI: 10.1038/nm0402-403. View

Bennett M . In-stent stenosis: pathology and implications for the development of drug eluting stents. Heart. 2003; 89(2):218-24. PMC: 1767562. DOI: 10.1136/heart.89.2.218. View

Forte A, Rinaldi B, Sodano L, Berrino L, Rossi F, Finicelli M . Stem cell therapy for arterial restenosis: potential parameters contributing to the success of bone marrow-derived mesenchymal stromal cells. Cardiovasc Drugs Ther. 2011; 26(1):9-21. DOI: 10.1007/s10557-011-6359-8. View

Mitra A, Agrawal D . In stent restenosis: bane of the stent era. J Clin Pathol. 2006; 59(3):232-9. PMC: 1860348. DOI: 10.1136/jcp.2005.025742. View

Cribbs S, Matthay M, Martin G . Stem cells in sepsis and acute lung injury. Crit Care Med. 2010; 38(12):2379-85. PMC: 3677751. DOI: 10.1097/CCM.0b013e3181f96f5f. View

Gray W, Granada J . Drug-coated balloons for the prevention of vascular restenosis. Circulation. 2010; 121(24):2672-80. DOI: 10.1161/CIRCULATIONAHA.110.936922. View

Kufner S, Cassese S, Valeskini M, Neumann F, Schulz-Schupke S, Hoppmann P . Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis: 3-Year Results of a Randomized Controlled Trial. JACC Cardiovasc Interv. 2015; 8(7):877-84. DOI: 10.1016/j.jcin.2015.01.031. View

10.

Pan J, Lu Z, Zhang J, Li M, Wei M . Angiographic patterns of in-stent restenosis classified by computed tomography in patients with drug-eluting stents: correlation with invasive coronary angiography. Eur Radiol. 2012; 23(1):101-7. DOI: 10.1007/s00330-012-2559-2. View

11.

Zhao Y, Wang H, Mazzone T . Identification of stem cells from human umbilical cord blood with embryonic and hematopoietic characteristics. Exp Cell Res. 2006; 312(13):2454-64. DOI: 10.1016/j.yexcr.2006.04.008. View

12.

Garcia-Garcia H, Garg S, Brugaletta S, Morocutti G, Ratner R, Kolatkar N . Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History). Int J Cardiovasc Imaging. 2011; 28(3):455-65. PMC: 3326367. DOI: 10.1007/s10554-011-9836-z. View

13.

Zhao Y, Lin B, Darflinger R, Zhang Y, Holterman M, Skidgel R . Human cord blood stem cell-modulated regulatory T lymphocytes reverse the autoimmune-caused type 1 diabetes in nonobese diabetic (NOD) mice. PLoS One. 2009; 4(1):e4226. PMC: 2627485. DOI: 10.1371/journal.pone.0004226. View

14.

Schiller N, McNamara D . Balloon catheter vascular injury of the alloxan-induced diabetic rabbit: the role of insulin-like growth factor-1. Mol Cell Biochem. 2000; 202(1-2):159-67. DOI: 10.1023/a:1007005919319. View

15.

Andriopoulou P, Navarro P, Zanetti A, Lampugnani M, Dejana E . Histamine induces tyrosine phosphorylation of endothelial cell-to-cell adherens junctions. Arterioscler Thromb Vasc Biol. 1999; 19(10):2286-97. DOI: 10.1161/01.atv.19.10.2286. View

16.

Hussain M, Theise N . Stem-cell therapy for diabetes mellitus. Lancet. 2004; 364(9429):203-5. DOI: 10.1016/S0140-6736(04)16635-X. View

17.

Demyanets S, Tentzeris I, Jarai R, Katsaros K, Farhan S, Wonnerth A . An increase of interleukin-33 serum levels after coronary stent implantation is associated with coronary in-stent restenosis. Cytokine. 2014; 67(2):65-70. PMC: 3996548. DOI: 10.1016/j.cyto.2014.02.014. View

18.

Rosenson R, Hurt-Camejo E . Phospholipase A2 enzymes and the risk of atherosclerosis. Eur Heart J. 2012; 33(23):2899-909. DOI: 10.1093/eurheartj/ehs148. View

19.

Puranik A, Dawson E, Peppas N . Recent advances in drug eluting stents. Int J Pharm. 2012; 441(1-2):665-79. PMC: 3567608. DOI: 10.1016/j.ijpharm.2012.10.029. View

20.

Silva I, Mello A, Damasceno N . Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A₂ (Lp-PLA₂): a review. Lipids Health Dis. 2011; 10:170. PMC: 3204246. DOI: 10.1186/1476-511X-10-170. View